Beam Therapeutics
Price & Volume
Stats
See moreOpen | $22.59 |
Previous Close | $22.19 |
Day Range | $21.71-$22.90 |
52W Range | $20.84-$35.25 |
Market Cap | $2.2B |
Shares Short | 9M |
Financials
See moreRevenue (12 Mos) | $63.5M |
Revenue Growth (YoY) | -90.5% |
Gross Profit (12 Mos) | -$304M |
Diluted EPS | -$4.64 |
News
See moreYahoo Finance • yesterday
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
Yahoo Finance • 19 days ago
Beam Therapeutics Announces Pricing of Underwritten Offering
Yahoo Finance • 19 days ago
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
Yahoo Finance • 24 days ago
Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%
About
CEO | Mr. John M. Evans M.B.A. |
Address | 238 Main Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 483 |
